{"product_id":"cdk2-antibody-bha17128537","title":"CDK2 Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eCDK2 Antibody is an antibody targeting \u003cstrong\u003eCDK2\u003c\/strong\u003e, raised in \u003cstrong\u003eMouse\u003c\/strong\u003e for protein detection and localization studies where these specifications are required.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e CDK2 (reported localization: Nuclear, cytoplasmic).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Monoclonal (mouse origin); Clone 5B12D1; Mouse IgG2a.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eConjugate\/label:\u003c\/strong\u003e Unconjugated (affects detection chemistry and multiplex compatibility).\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human, Mouse, Rat.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eListed applications:\u003c\/strong\u003e WB, IHC-P, FACS (refer to on-page specifications for application-specific guidance).\u003c\/li\u003e \u003c\/ul\u003e  \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eCDK2, Cyclin-Dependent Kinase2, is also known as P33. The CDK2 protein was highly homologous to p34 (CDC2) kinase and more significantly homologous to Xenopus Eg1 kinase, suggesting that CDK2 is the human homolog of Eg1. The CDK2 gene is mapped to 12q13, the same region to which the CDK4 gene maps. Human cyclin A binds independently to 2 kinases, p34 (cdc2) or p33. In adenovirus-transformed cells, the viral E1A oncoprotein seems to associate with p33\/cyclin A but not with p34 (cdc2)\/cyclin A. The gene for p33 shares 65% sequence identity with p34 (cdc2). P33 (cdk2) plays a unique role in cell cycle regulation of vertebrate cells.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eComparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).\u003c\/li\u003e \u003cli\u003eSubcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.\u003c\/li\u003e \u003cli\u003eIntegration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eWestern blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eImmunohistochemistry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003cli\u003eFlow cytometry: researchers commonly compare relative signal levels across conditions and use appropriate negative\/positive controls for interpretation.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eInterpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands\/signals accordingly.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eEpitope context:\u003c\/strong\u003e binding can depend on protein conformation and sample processing; region information in the title\/immunogen can help anticipate what may be detected.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eSpecies differences:\u003c\/strong\u003e predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include negative controls (no-primary\/isotype), and where possible genetic controls (KO\/KD) or independent antibodies to strengthen conclusions.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry P24941 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/P24941 - Gene search: CDK2 — NCBI Gene — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=CDK2 - Ensembl search: CDK2 — Ensembl — https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=CDK2 - PubMed search: CDK2 antibody — PubMed — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=CDK2+antibody - Reactome search: CDK2 — Reactome — https:\/\/reactome.org\/content\/query?q=CDK2 --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53046425223533,"sku":"RQ6965","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_c593e72a-9fdd-4e10-9516-57e9966f3574.jpg?v=1772000552","url":"https:\/\/www.ebiohippo.com\/products\/cdk2-antibody-bha17128537","provider":"BioHippo","version":"1.0","type":"link"}